Loading
Arena Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Munshi Amit, was filed 17 Aug 2021.
Arena Pharmaceuticals Inc: what insiders have been doing
This page follows insider dealings at Arena Pharmaceuticals Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in San Diego, United States. The group dates from 1997. Arena Pharmaceuticals Inc has had no insider filing for more than a year; the last one goes back to 11 March 2022.
Our records for Arena Pharmaceuticals Inc go back to 2016, with 7 purchases and 65 sales on the open market in total.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
237
Thresholds
n/a
Buy Volume
€221,564
7 ops. · all time
Sell Volume
€42M
65 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$46.5k
Net income-US$530.7M-1141542.6% margin
Last declaration on 11 March 2022
Declarations237 total
3,067 sharesCommon StockSEC:0001628280-22-005918:1
3,067 sharesCommon StockSEC:0001628280-22-005908:1
6,660 sharesCommon StockSEC:0001628280-22-005891:1
21,462 sharesCommon StockSEC:0001628280-22-005891:2
3,665 sharesCommon StockSEC:0001628280-22-005906:1
21,462 sharesCommon StockSEC:0001628280-22-005892:1
250 sharesCommon StockSEC:0001628280-22-005889:1
28,800 sharesCommon StockSEC:0001628280-22-005889:2
85,847 sharesCommon StockSEC:0001628280-22-005889:3
8,167 sharesCommon StockSEC:0001628280-22-005916:1
6,660 sharesCommon StockSEC:0001628280-22-005885:1
21,462 sharesCommon StockSEC:0001628280-22-005885:2
3,067 sharesCommon StockSEC:0001628280-22-005912:1
6,660 sharesCommon StockSEC:0001628280-22-005884:1
21,462 sharesCommon StockSEC:0001628280-22-005884:2
6,660 sharesCommon StockSEC:0001628280-22-005887:1
21,462 sharesCommon StockSEC:0001628280-22-005887:2
3,882 sharesCommon StockSEC:0001628280-22-005914:1
3,067 sharesCommon StockSEC:0001628280-22-005913:1
1,116 sharesCommon StockSEC:0001628280-22-005915:1
8,167 sharesCommon StockSEC:0001628280-22-005915:2
8,150 sharesCommon StockSEC:0001628280-22-005912:0
17,776 sharesCommon StockSEC:0001628280-22-005918:0
9,086 sharesCommon StockSEC:0001628280-22-005891:0
10,500 shares@ US$98.5188.1% of flowCommon StockSEC:0001628280-22-005889:0
25 of 237 declarations
About Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc. was a United States-based biopharmaceutical company focused on small-molecule therapies for immuno-inflammatory and cardiovascular diseases. The company was founded in 1997 and was headquartered in San Diego, California, United States, with additional operating hubs in the U.S. and Europe before its acquisition. Arena’s business model was that of a research-driven clinical-stage biotech rather than a commercial, diversified pharmaceutical group. Its best-known programs included etrasimod, an oral, selective sphingosine-1-phosphate (S1P) receptor modulator developed for immune-mediated diseases, along with cardiovascular development assets such as temanogrel and APD418. Over time, Arena also explored other candidates across gastroenterology, dermatology, pain, and inflammatory conditions, reflecting a pipeline strategy aimed at high-unmet-need indications and differentiated mechanisms of action. From a competitive standpoint, Arena operated in a crowded biotech landscape where success depended on clinical data, regulatory execution, and the ability to secure strategic partnerships or a larger pharmaceutical acquirer. That outcome ultimately materialized: Pfizer announced the acquisition of Arena in December 2021 and completed it in March 2022 for about $6.7 billion in cash. As part of that transaction, Arena became a wholly owned subsidiary of Pfizer and its shares were delisted from the Nasdaq Global Select Market. Therefore, while ARNA may still appear in SEC archives and historical insider-transaction records, it is no longer an independent listed equity on NYSE/NASDAQ. For investors following SEC Form 4 activity, the practical interpretation is that Arena is a legacy ticker with historical biotech relevance rather than an active standalone public company. Its key recent corporate milestone was the Pfizer takeover, which effectively transferred the economic and development value of Arena’s pipeline into Pfizer’s inflammation and immunology franchise.
